SGCG and nervous system disorder: Genetically modified mice defective for type I and/or type II interferon signaling, or wild-type mice with the interferon response suppressed by antibodies, develop more systemic infections with viremia; neurologic disease; high viral loads in the brain, spinal cord, and testes; and age-dependent mortality (16, 17).